120757

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

120757 [2018/11/22 21:16] (current)
Line 1: Line 1:
 +====== Sodium valproate in the treatment of cerebellar disorders.======
 +
 +** Article date:** 1979/11/1
 +~~META:date created = 1979-11-01~~
 +
 +** PubMed ID: 120757 **
 +
 +** Journal name: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (ISSN: 0317-1671) **
 +
 +** ABSTRACT **
 +
 +Because of the high concentrations of gamma-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.
 +
 +===== ===== 
 +
 +{{gview 100%,​450px>​ http://​directlinks.cc/​files/​muscimol/​120757.pdf}}
 +
 +Author List: Neophytides A N, Teychenne P F, Pfeiffer R F, Calne D B
 +
 +Publication Types: Clinical Trial; Controlled Clinical Trial; Journal Article
 +
 +Substances mentioned in the article: Muscimol; Clonazepam; Valproic Acid; 
 +
 +Mesh terms: Cerebellar Diseases/​drug therapy; Clonazepam/​therapeutic use; Double-Blind Method; Female; Humans; Male; Muscimol/​therapeutic use; Valproic Acid/​administration & dosage; ​
 +
 +{{tag> Clonazepam Valproic_Acid Muscimol }}
 +
 +{{keywords>​ Clonazepam, Valproic Acid, Muscimol}}
 +
  
120757.txt · Last modified: 2018/11/22 21:16 (external edit)